|
There
are primarily two theories as to how GH exerts its
growth promoting effects. The first theory is called
the Dual Effector theory. The second theory is called
the Somatomedin ("mediator of growth") Hypothesis.
Both theories are fairly strait forward. Let?s start
with the Dual Effector theory.
The Dual Effector theory states that GH itself
has anabolic effects directly on body tissues. This
theory has been supported by studies looking at
the effects of injecting GH directly into growth
plates. Genetically altered strains of mice have
also help to support this theory. When comparing
mice that genetically over express GH and mice that
over express insulin-like growth factor-1 (IGF-1),
GH mice are larger. Those who support the dual effector
theory site this evidence. Interestingly, when IGF-1
antiserum (it destroys IGF-1) is administered concomitantly
with GH, all of the anabolic effects of GH are abolished.
Clearly IGF-1 has got to be involved somewhere between
the pituitary and the target tissue (i.e. muscle).
The Somatomedin hypothesis clears things up somewhat.
The Somatomedin hypothesis states that GH exerts
its growth promoting effects through IGF-1. More
specifically, GH is first released from the pituitary
and then travels to the liver and other peripheral
tissues where it causes the synthesis and release
of IGFs. IGFs work as endocrine growth factors,
meaning that they travel in the blood to the target
tissues after being released from cells that produced
it, specifically the liver in this case. Many studies
have been performed showing that animals that are
GH deficient, systemic IGF-1 infusions lead to normal
growth. Admittedly, the effects are similar to those
observed after GH administration. In fact, additional
studies have shown IGF-1 to be greatly inferior
as an endocrine growth factor requiring almost
50 times the amount to exert that same effects of
GH. Recently rhIGF-1 has become widely more available
and is currently approved form the treatment of
HIV associated wasting. This increased availability
allowed testing of this hypothesis in humans. Studies
in human subjects with GH insensitivity (Laron syndrome)
have consistently validated the somatomedin hypothesis
(Rank, 1995; Savage, 1993). These results indicate
that although IGF-1 might be the mediator of GH
effects, it's not as simple as just getting the
liver to release IGF-1.
So the main difference between these two theories
is that the Dual effector theory states that GH
doesn?t necessarily need IGF-1 to work, the Somatomedin
hypothesis insists it does. In reality both theories
are correct. It?s just that the Somatomedin hypothesis
focuses on "circulating" IGF-1, the Dual Effector
theory recognizes that although IGF-1 is still the
active hormone, it doesn't have to come from the
blood (liver), it can be produced on location by
the very cells that use it.
In summary, by combining the Dual Effector theory
and the Somatomedin hypothesis there are three main
mechanisms by which GH makes things grow. First,
the effects of GH on bone formation and organ growth
are mediated by the endocrine action of IGF-1. As
stated in the Somatomedin hypothesis, GH, released
from the pituitary, causes increased production
and release of IGF-1 into the general circulation.
IGF-1 then travels to target tissues such as bones,
organs, and muscle to cause anabolic effects.
Second, GH regulates the activity of IGF-1 by
increasing the production of binding proteins (specifically
IGFBP-3 and another important protein called the
acid-labile subunit) that increase the half-life
of IGF-1 from minutes to hours. Circulating proteases
then act to break up the binding protein/hormone
complex thereby releasing the IGF-1 in a controlled
fashion over time. GH may even cause target tissues
to produce IGFBP-3 increasing its effectiveness
locally.
Third, GH may influence the activity of IGF-1
on an autocrine/paracrine level. Autocrine means
that a hormone has an effect on the cell that produced
it, paracrine means to have an effect on the "cell(s)"
next to it as well. This is a completely localized
effect, not dependent on the blood stream to carry
things where you want them. Muscle growth from weight
training is the result of IGF-1 being produced by
the muscle cells themselves, not the liver. In fact,
IGF-1 form the liver is genetically different from
IGF-1 produced in your muscles. This information
should explain why using IGF-1 systemically (from
the blood stream) has been a hit and miss proposition.
In order to sufficiently address the role of
GH and IGF-1 in muscle growth, we need to explore
the mechanism of not only IGF-1?s autocrine/paracrine
actions, but also the mechanisms of muscle growth
itself.
The ability of muscle tissue to constantly regenerate
in response to activity makes it unique. Its ability
to respond to physical/mechanical stimuli depends
greatly on what are called satellite cells. Satellite
cells are muscle precursor cells. You might think
of them as "pro-muscle" cells. They are cells that
reside on and around muscle cells. These cells sit
dormant until called upon by growth factors such
as IGF-1. Under the influence of IGF-1 these cells
divide (proliferate) and genetically change (differentiation)
into cells that have nuclei identical to those of
muscle cells. These new satellite cells with muscle
nuclei are critical if not mandatory to muscle growth.
Without the ability to increase the number of
nuclei, a muscle cell will not grow larger and its
ability to repair itself is limited. The explanation
for this is quite simple. The nucleus of the cell
is where all of the blue prints for new muscle proteins
come from. The larger the muscle, the more nuclei
you need to maintain protein synthesis. There is
a "nuclear to volume" ratio that cannot be overridden.
Whenever a muscle grows in response to mechanical
overload (i.e. weight training) there is a positive
correlation between the increase in the number of
myonuclei and the increase in muscle cell's cross
sectional area (CSA). When satellite cells are prohibited
from donating new nuclei, overloaded muscle will
not grow. So you see, one important key to exercise
induced muscle growth is the activation of satellite
cells by growth factors such as IGF-1.
Few people realize that you can inject a muscle
with IGF-1 and it will grow! Studies have shown
that, when injected locally, IGF-1 increases satellite
cell activity, muscle DNA content, muscle protein
content, muscle weight and muscle cross sectional
area. I'm not really sure why someone would
choose to inject oil instead of IGF-1. Oil gives
you lumps and causes your peers to make jokes about
you behind your back. IGF-1 just makes the muscle
grow and leaves people wondering how you brought
up those lagging rear delts.
Scientists are now figuring out the signaling
pathway by which mechanical stimulation and IGF-1
activity leads to all of the above changes in satellite
cells, muscle DNA content, muscle protein content,
muscle weight and muscle cross sectional area just
outlined above. This research is stemming from studies
done to explain cardiac hypertrophy. It involves
a muscle enzyme called calcineurin which is a phosphatase
enzyme activated by high intracellular calcium ion
concentrations (Dunn, 1999). Note that overloaded
muscle is characterized by chronically elevated
intracellular calcium ion concentrations. Other
recent research has demonstrated that IGF-1 increases
intracellular calcium ion concentrations leading
to the activation of the calcineurin signaling pathway,
and subsequent muscle fiber hypertrophy. I am by
no means a geneticist so I hesitated even bringing
this research up. To avoid confusion I will enlist
the help of the people doing the research. The researchers
involved in these studies have explained it this
way, IGF-1 as well as activated calcineurin, induces
expression of the transcription factor GATA-2, which
accumulates in a subset of myocyte nuclei, where
it associates with calcineurin and a specific dephosphorylated
isoform of the transcription factor nuclear factor
of activated T cells or NF-ATc1. Thus, IGF-1 induces
calcineurin-mediated signaling and activation of
GATA-2, a marker of skeletal muscle hypertrophy,
which cooperates with selected NF-ATc isoforms to
activate gene expression programs leading to increased
contractile protein synthesis and muscle hypertrophy.
Simple huh?
Anybody really interested in how muscles grow
is going to have to brush up on their genetics (including
myself). Until then please don't send me a barrage
of questions about GATA-2 or NF-Atc isoforms. These
aren't things we know how to directly manipulate
with supplements yet.
hGH Resources
Human Growth Hormone Pictures
Saizen Prescribing Information
Visit Our Forums to Learn More About Anabolic Steroids
|